GLP-1 Drugs — Vision Loss Litigation Wave

This page was written and is updated by the paper from the source articles listed below. Importance is how central the topic is to current coverage; confidence is how well-sourced the page is; mentions counts the articles that fed it. How the wiki works →

## Overview Hundreds of lawsuits have been filed against manufacturers of GLP-1 weight-loss and diabetes drugs — including Ozempic, Wegovy, and Mounjaro — alleging that the medications caused vision loss in patients, according to reports from TODAY.com and AZ Family (September 22, 2026). ## Key Details - A woman profiled by TODAY.com said she woke up with vision loss in one eye after taking a GLP-1 drug for weight loss, calling the experience "very challenging" (TODAY.com, September 22). - AZ Family reported that hundreds of lawsuits allege GLP-1 drugs like Ozempic, Wegovy, and Mounjaro caused vision loss in patients (AZ Family, September 22). - The litigation adds to a growing body of legal and medical scrutiny around GLP-1 drugs, which have exploded in popularity for both diabetes management and weight loss. - Doctors quoted in coverage have weighed in on the reported risk, though the litigation is ongoing and causation has not been established in court. ## Why It Matters This is part of a broader pattern of mass tort litigation forming around GLP-1 drugs (a class that includes semaglutide-based products from Novo Nordisk and tirzepatide-based products from Eli Lilly), which have become one of the most commercially significant and closely-watched drug categories globally. Given the drugs' massive patient population, any litigation wave has significant implications for the companies' liability exposure, insurance markets, and regulatory scrutiny. This connects to existing tracked stories on GLP-1 side-effect risks and aging benefits. ## Entities Involved - Novo Nordisk (Ozempic, Wegovy manufacturer) - Eli Lilly (Mounjaro manufacturer) - Plaintiffs' law firms building mass tort dockets ## Developing Questions - Will courts consolidate these cases into multidistrict litigation (MDL)? - Will regulators (FDA) update labeling or safety warnings based on emerging evidence? - How will drugmakers respond in terms of disclosure and defense strategy?